- Published on
Infectious Disease And Microbiology – Empyema
Empyema is defined as the accumulation of purulent (pus-containing) fluid within the pleural cavity. It most commonly develops as a complication of bacterial pneumonia but may also arise following thoracic surgery, trauma, esophageal perforation, or subdiaphragmatic infections. In children, empyema is usually secondary to pneumonia—most often caused by Streptococcus pneumoniae—and tends to have a better prognosis than in adults, although management principles are similar. Overall, pleural effusions occur in up to 57% of pneumonia cases, but only about 1–2% progress to empyema. The condition affects individuals of all ages, with higher prevalence in the elderly and in children, and occurs more frequently in males.
Several risk factors predispose individuals to empyema, including diabetes mellitus, alcoholism, substance abuse, rheumatoid arthritis, chronic lung disease, poor dental hygiene, malignancy, and prior thoracic surgery. Conditions that increase the risk of aspiration are particularly associated with anaerobic infections. Prevention focuses on appropriate treatment of pneumonia, adherence to surgical infection control practices, and vaccination (especially pneumococcal vaccination).
The development of empyema progresses through three stages. The exudative stage involves inflammation and fluid accumulation in the pleural space. This is followed by the fibrinopurulent stage, characterized by fibrin deposition and pus formation. Finally, the organizing stage occurs, where fibroblasts proliferate and collagen is deposited, potentially leading to pleural thickening and restricted lung expansion. The causative organisms vary depending on whether the infection is community-acquired or hospital-acquired. Community-acquired empyema commonly involves streptococci, staphylococci, anaerobes, and Enterobacteriaceae, while hospital-acquired cases are more often caused by methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, enterococci, and other resistant organisms.
Clinically, patients often present with a history of pneumonia or thoracic procedures, along with symptoms such as fever, chest pain, and shortness of breath. In elderly or immunocompromised patients, symptoms may be subtle, including weight loss or anemia. On physical examination, findings may include dullness to percussion, decreased tactile fremitus, and absent breath sounds over the affected area, although small effusions may not produce obvious signs.
Diagnosis is confirmed through thoracentesis, with the presence of pus in the pleural space being definitive. Laboratory evaluation includes complete blood count and inflammatory markers such as C-reactive protein. Pleural fluid analysis is essential and typically shows low pH (<7.2), high white blood cell count, and positive Gram stain or culture. Imaging plays a key role: chest X-ray identifies pleural effusion, ultrasound helps localize fluid and guide drainage, and CT scan can distinguish empyema from lung abscess (notably showing the “split pleura” sign).
The differential diagnosis includes other causes of pleural effusion, lung abscess, and pneumonia. Management requires prompt initiation of antimicrobial therapy along with drainage of the infected fluid, usually via chest tube. Antibiotic regimens differ based on whether the infection is community- or hospital-acquired and should cover likely pathogens, including anaerobes and resistant organisms where appropriate. Adjunctive treatments include adequate hydration, nutritional support, and, in some cases, intrapleural fibrinolytic therapy to improve drainage.
In cases where drainage is incomplete or complications arise, surgical intervention may be necessary. Options include video-assisted thoracoscopic surgery (VATS), thoracotomy with decortication, or other open surgical procedures. Most patients require hospitalization for intravenous antibiotics and monitoring. Follow-up involves continued antibiotic therapy for 2–4 weeks, monitoring inflammatory markers, and ensuring adequate drainage. Chest tubes are typically removed once drainage decreases and fluid clears.
The prognosis of empyema varies depending on patient factors and timeliness of treatment. While many patients recover with appropriate management, mortality rates range from 7% to 33% within one year and may exceed 50% in patients with significant comorbidities. Complications include pleural thickening, pulmonary fibrosis, pneumothorax, bronchopleural fistula, respiratory failure, septic shock, and, in rare cases, empyema necessitatis.
- Published on
Infectious Disease and Microbiology – Ehrlichiosis and Anaplasmosis
Ehrlichiosis and anaplasmosis are systemic infections caused by obligate intracellular bacteria belonging to the family Anaplasmataceae, which includes the genera Ehrlichia, Anaplasma, Neorickettsia, and Wolbachia. These organisms primarily infect humans through tick bites, especially during the summer months when tick activity is highest. They target cells of the reticuloendothelial system, particularly monocytes and granulocytes, leading to a wide range of clinical manifestations. In immunocompetent individuals, the disease is often mild to moderate, presenting with nonspecific symptoms such as fever, malaise, headache, myalgias, nausea, and vomiting. However, in immunocompromised patients, including those with AIDS or on corticosteroid therapy, infections may become severe, with central nervous system involvement, multiple organ dysfunction, and even death.
Epidemiologically, ehrlichiosis and anaplasmosis are primarily reported in the United States but also occur worldwide. Human monocytic ehrlichiosis (HME), caused by Ehrlichia chaffeensis, is transmitted mainly by the tick Amblyomma americanum, particularly in the southeastern and south-central US. Human granulocytic anaplasmosis (HGA), caused by Anaplasma phagocytophilum, is transmitted by Ixodes scapularis, with most cases reported in regions such as Wisconsin, Minnesota, New England, New Jersey, and New York. Cases are also reported in parts of Europe. Subclinical infections are common, and many cases are underdiagnosed. Coinfections with other tick-borne pathogens, such as Babesia microti and Borrelia burgdorferi, may occur due to shared vectors.
Risk factors include exposure to tick-infested environments, outdoor activities in endemic areas, and immunosuppression. Prevention focuses on avoiding tick bites by wearing protective clothing, using insect repellents containing DEET, and performing thorough body checks after potential exposure. Prompt removal of ticks is essential to reduce transmission risk.
The pathophysiology involves bacterial invasion of host immune cells, where the organisms reside within membrane-bound vacuoles. Ehrlichia chaffeensis primarily infects macrophages, while Anaplasma phagocytophilum targets granulocytes. These infections lead to hematologic abnormalities such as leukopenia and thrombocytopenia, as well as systemic inflammation. If untreated, the disease can progress to severe multisystem involvement.
Clinically, symptoms usually develop about 7 days after a tick bite. Patients present with fever, malaise, headache, myalgias, nausea, and sometimes rash, which may be maculopapular or hemorrhagic. Lymphadenopathy and hepatosplenomegaly may occur. Severe cases can progress to septic shock, acute respiratory distress syndrome, and neurological complications such as seizures or coma. Human granulocytic anaplasmosis presents similarly but may lack rash unless there is coinfection with other tick-borne diseases.
Diagnosis is based on clinical suspicion supported by laboratory findings. Common laboratory abnormalities include leukopenia, thrombocytopenia, anemia, and elevated liver enzymes. Serologic testing using indirect immunofluorescence is considered the gold standard but may be negative early in the disease. Polymerase chain reaction (PCR) testing offers higher sensitivity during acute infection but requires specialized laboratories. Blood smear examination has low sensitivity. Imaging such as chest X-ray may show findings consistent with acute respiratory distress syndrome in severe cases.
The differential diagnosis includes other infectious and noninfectious conditions such as endocarditis, septicemia, vasculitis, thrombotic thrombocytopenic purpura, and other tick-borne illnesses including tularemia, babesiosis, Lyme disease, Rocky Mountain spotted fever, and murine typhus.
Treatment should be initiated promptly when the disease is suspected. Doxycycline is the first-line therapy and is effective for both ehrlichiosis and anaplasmosis, typically resulting in clinical improvement within 24–48 hours. Treatment duration is usually 7–14 days. In cases where doxycycline cannot be used, such as pregnancy, rifampin may be considered. Chloramphenicol has been used but is less reliable and may not be effective in all cases.
Follow-up is important to ensure clinical improvement, as lack of response within 48 hours should prompt reconsideration of the diagnosis. Persistent infection has been reported despite treatment, and expert consultation may be necessary in complicated cases.
Complications can be severe, particularly if untreated. These include respiratory failure, neurological involvement, acute renal failure, gastrointestinal hemorrhage, and death. Hospitalization is common, with a significant proportion of patients developing severe disease. Mortality rates are estimated at 2–5%, with higher risk in elderly and immunocompromised individuals.
- Published on
Infectious Disease and Microbiology – Echinococcosis
Echinococcosis, also known as hydatid disease, is a parasitic infection caused by species of the genus Echinococcus. The most important species include Echinococcus granulosus, which causes cystic echinococcosis (CE), Echinococcus multilocularis, which causes alveolar echinococcosis (AE), and Echinococcus vogeli, which causes polycystic echinococcosis. These infections are characterized by the formation of cysts in various organs, most commonly the liver and lungs.
The disease is endemic in many parts of the world. Cystic echinococcosis is prevalent in Central Asia, South America, and North Africa, while alveolar echinococcosis is increasingly reported in Central Europe and is highly endemic in parts of China. Polycystic echinococcosis is rare and primarily found in Latin America. Transmission is closely associated with rural environments and animal husbandry practices. Humans acquire infection through contact with infected definitive hosts, typically dogs in CE and foxes or wild canids in AE, or through ingestion of food or water contaminated with parasite eggs.
Risk factors include close contact with dogs or other canines, exposure to livestock such as sheep, poor hygiene, and residence in endemic rural areas. Inadequate slaughterhouse practices and allowing dogs access to infected animal viscera perpetuate the parasite’s lifecycle. Preventive measures focus on improved hygiene, control of stray dog populations, proper disposal of animal remains, and vaccination of livestock.
After ingestion, parasite eggs hatch in the intestine, and larvae penetrate the intestinal wall to enter the bloodstream. They are carried to target organs, most commonly the liver (about 65%) and lungs (about 20%), where they develop into slowly growing cysts. These cysts may produce daughter cysts and can enlarge over time, causing pressure effects. In alveolar echinococcosis, lesions are typically infiltrative and destructive, resembling malignant tumors such as hepatocellular carcinoma and often confined to the liver.
Clinically, cystic echinococcosis is often asymptomatic and discovered incidentally. Symptoms arise due to mass effect depending on the organ involved. Complications include cyst rupture, which may lead to anaphylactic shock, dissemination of infection, or communication with adjacent structures such as the biliary tract or bronchial tree. Physical examination findings are often minimal, though hepatomegaly or a palpable mass may be present.
Diagnosis relies primarily on imaging and serology. Ultrasound is the initial modality of choice, particularly for hepatic cysts, and may reveal characteristic features such as daughter cysts, multilocular appearance, or specific signs like the “water lily” sign. CT and MRI provide further characterization. Serologic testing, typically using ELISA, supports the diagnosis, although sensitivity varies. Eosinophilia may be present but is not consistent. Cyst puncture is generally contraindicated due to the risk of anaphylaxis and parasite dissemination.
Treatment depends on the type and stage of disease. Surgical removal of cysts is the mainstay of treatment for cystic echinococcosis and is often curative. Albendazole is the primary pharmacologic therapy and is used in inoperable cases, disseminated disease, or as adjunctive therapy before and after surgery. Mebendazole is less effective, while praziquantel may be used as an adjunct in selected cases. A less invasive approach, known as PAIR (puncture, aspiration, injection, reaspiration), is used in selected cases and has shown promising results when combined with antiparasitic therapy.
Alveolar echinococcosis requires more aggressive management, often involving radical surgery combined with long-term albendazole therapy, though outcomes are less favorable compared to cystic disease. Follow-up is mainly performed using imaging to monitor cyst progression or recurrence.
Prognosis is generally excellent for cystic echinococcosis with appropriate treatment, whereas alveolar echinococcosis carries a higher mortality if untreated. Complications include cyst rupture with anaphylaxis, secondary infection, dissemination of the parasite, and in AE, progressive tissue destruction with metastatic-like spread.
Echinococcosis, also known as hydatid disease, is a parasitic infection caused by species of the genus Echinococcus. The most important species include Echinococcus granulosus, which causes cystic echinococcosis (CE), Echinococcus multilocularis, which causes alveolar echinococcosis (AE), and Echinococcus vogeli, which causes polycystic echinococcosis. These infections are characterized by the formation of cysts in various organs, most commonly the liver and lungs.
The disease is endemic in many parts of the world. Cystic echinococcosis is prevalent in Central Asia, South America, and North Africa, while alveolar echinococcosis is increasingly reported in Central Europe and is highly endemic in parts of China. Polycystic echinococcosis is rare and primarily found in Latin America. Transmission is closely associated with rural environments and animal husbandry practices. Humans acquire infection through contact with infected definitive hosts, typically dogs in CE and foxes or wild canids in AE, or through ingestion of food or water contaminated with parasite eggs.
Risk factors include close contact with dogs or other canines, exposure to livestock such as sheep, poor hygiene, and residence in endemic rural areas. Inadequate slaughterhouse practices and allowing dogs access to infected animal viscera perpetuate the parasite’s lifecycle. Preventive measures focus on improved hygiene, control of stray dog populations, proper disposal of animal remains, and vaccination of livestock.
After ingestion, parasite eggs hatch in the intestine, and larvae penetrate the intestinal wall to enter the bloodstream. They are carried to target organs, most commonly the liver (about 65%) and lungs (about 20%), where they develop into slowly growing cysts. These cysts may produce daughter cysts and can enlarge over time, causing pressure effects. In alveolar echinococcosis, lesions are typically infiltrative and destructive, resembling malignant tumors such as hepatocellular carcinoma and often confined to the liver.
Clinically, cystic echinococcosis is often asymptomatic and discovered incidentally. Symptoms arise due to mass effect depending on the organ involved. Complications include cyst rupture, which may lead to anaphylactic shock, dissemination of infection, or communication with adjacent structures such as the biliary tract or bronchial tree. Physical examination findings are often minimal, though hepatomegaly or a palpable mass may be present.
Diagnosis relies primarily on imaging and serology. Ultrasound is the initial modality of choice, particularly for hepatic cysts, and may reveal characteristic features such as daughter cysts, multilocular appearance, or specific signs like the “water lily” sign. CT and MRI provide further characterization. Serologic testing, typically using ELISA, supports the diagnosis, although sensitivity varies. Eosinophilia may be present but is not consistent. Cyst puncture is generally contraindicated due to the risk of anaphylaxis and parasite dissemination.
Treatment depends on the type and stage of disease. Surgical removal of cysts is the mainstay of treatment for cystic echinococcosis and is often curative. Albendazole is the primary pharmacologic therapy and is used in inoperable cases, disseminated disease, or as adjunctive therapy before and after surgery. Mebendazole is less effective, while praziquantel may be used as an adjunct in selected cases. A less invasive approach, known as PAIR (puncture, aspiration, injection, reaspiration), is used in selected cases and has shown promising results when combined with antiparasitic therapy.
Alveolar echinococcosis requires more aggressive management, often involving radical surgery combined with long-term albendazole therapy, though outcomes are less favorable compared to cystic disease. Follow-up is mainly performed using imaging to monitor cyst progression or recurrence.
Prognosis is generally excellent for cystic echinococcosis with appropriate treatment, whereas alveolar echinococcosis carries a higher mortality if untreated. Complications include cyst rupture with anaphylaxis, secondary infection, dissemination of the parasite, and in AE, progressive tissue destruction with metastatic-like spread.
- Published on
Infectious Disease and Microbiology – E. coli Infections
Escherichia coli are Gram-negative, rod-shaped bacteria that are part of the normal intestinal flora but can also cause a wide range of infections. They are among the most important pathogens in both community-acquired and hospital-acquired infections.
Epidemiologically, E. coli is the leading cause of nosocomial bacteremia and is responsible for more than 80% of acute uncomplicated urinary tract infections in young women. It is also a major cause of traveler’s diarrhea, typically acquired via the fecal–oral route through contaminated food or water, especially in tropical and subtropical regions. Urinary tract infections often occur due to colonization of the periurethral area followed by ascending infection. Risk factors in women include sexual activity and use of spermicides or diaphragms. In men, risks include lack of circumcision, anal intercourse, and exposure to colonized partners. Immunocompromised individuals, including those with HIV (especially CD4 <200), are also at increased risk.
Additional risk factors include anatomical abnormalities such as urinary obstruction or stones, immunosuppression (e.g., diabetes, malignancy, steroid use), and certain host susceptibility factors such as inability to secrete blood group antigens, which facilitates bacterial adherence. Preventive strategies include careful use of antibiotic prophylaxis in selected travelers and avoiding unnecessary screening for asymptomatic bacteriuria except in specific groups such as pregnant women.
The pathophysiology of E. coli infections is based on its ability to adhere to host cells and produce toxins. Different strains have distinct pathogenic mechanisms. Enterotoxigenic E. coli (ETEC) produces toxins that increase cyclic nucleotide levels, leading to increased chloride secretion and watery diarrhea. Enteropathogenic strains disrupt intestinal mucosa, especially in children. Enteroinvasive strains invade intestinal cells, causing inflammatory diarrhea. Enterohemorrhagic E. coli (EHEC), such as O157:H7, produces Shiga toxin and can cause hemorrhagic colitis and hemolytic–uremic syndrome, often associated with contaminated beef or dairy products. Enteroaggregative strains are linked to persistent diarrhea, particularly in travelers and immunocompromised patients.
Uropathogenic E. coli strains possess specific virulence factors, including pili that allow adherence to uroepithelial cells, leading to infections ranging from cystitis to pyelonephritis and even septicemia. Beyond the urinary and gastrointestinal systems, E. coli can cause intra-abdominal infections such as abscesses, cholecystitis, and cholangitis. It is also associated with serious conditions including meningitis in neonates, as well as endocarditis, pneumonia, osteomyelitis, septic arthritis, and other systemic infections.
Diagnosis is confirmed by isolating E. coli from normally sterile sites such as blood, cerebrospinal fluid, or bile. In diarrheal illness, specialized testing such as PCR or toxin detection may be required to identify specific pathogenic strains. Imaging studies like abdominal CT or ultrasound may help identify complications such as abscesses or hepatobiliary infections. The differential diagnosis depends on the clinical presentation and includes other bacterial causes such as Campylobacter, Salmonella, and Shigella, particularly in cases of bloody diarrhea.
Treatment depends on the type and severity of infection. Localized infections require both antimicrobial therapy and, when necessary, drainage of abscesses or removal of infected material. Traveler’s diarrhea is commonly treated with short courses of fluoroquinolones or trimethoprim–sulfamethoxazole, along with supportive therapy such as hydration and antidiarrheal agents. However, antibiotics are generally avoided in EHEC infections due to the risk of worsening toxin-mediated complications such as hemolytic–uremic syndrome.
Uncomplicated cystitis is treated with short courses of oral antibiotics, while pyelonephritis requires longer treatment and sometimes hospitalization for intravenous therapy. Severe infections such as bacteremia or sepsis require broad-spectrum intravenous antibiotics, including fluoroquinolones, third-generation cephalosporins, or carbapenems. Pregnant patients require specific antibiotic choices such as penicillins, cephalosporins, or nitrofurantoin.
Follow-up is important in patients with persistent bacteremia or recurrent infections, as these may indicate underlying abnormalities such as abscesses, urinary tract obstruction, or foreign bodies. Prognosis is generally good with appropriate treatment, although complications such as dehydration, septic shock, and hemolytic–uremic syndrome can occur. Severe systemic infections may be life-threatening, particularly in vulnerable populations such as those with liver disease, immunosuppression, or impaired immune function.
- Published on
Infectious Disease and Microbiology – Diverticulitis
Diverticulitis is an inflammatory condition of a diverticulum, which is a pouch formed by herniation of the mucosal layer through a weak point in the muscular wall of the gastrointestinal tract. While diverticula can occur throughout the GI tract, they are most commonly found in the colon, particularly where the vasa recta penetrate the bowel wall. The presence of diverticula without inflammation is referred to as diverticulosis or diverticular disease, whereas diverticulitis specifically indicates inflammation and possible infection.
The condition is more prevalent in Western populations and increases significantly with age, affecting fewer than 5% of individuals under 40 years old but up to 65–80% of those over 70. It accounts for more than 130,000 hospital admissions annually in the United States. Both males and females are affected equally. In Western countries, diverticulitis typically involves the descending and sigmoid colon, whereas right-sided disease is more common in Asian populations.
Risk factors include a low-fiber diet, which leads to decreased stool bulk and increased intraluminal pressure, obesity, sedentary lifestyle, and immunosuppression (e.g., organ transplant recipients). The underlying mechanism involves increased pressure within the colon at weak points, leading to formation of diverticula. Subsequent pressure and irritation can result in inflammation, microperforations, or infection by polymicrobial flora, particularly anaerobes and gram-negative bacteria. Complicated diverticulitis may involve abscess formation, peritonitis, or fistula development and is classified using Hinchey’s staging system.
Clinically, diverticulitis presents with variable severity. Common symptoms include low-grade fever, abdominal pain that often starts in the epigastric region and localizes to the left lower quadrant, and changes in bowel habits such as constipation or diarrhea. In severe cases, perforation may lead to peritoneal signs like guarding and rebound tenderness. Patients with fistula formation may report pneumaturia, fecaluria, or recurrent urinary tract infections.
On physical examination, tenderness is usually localized to the left lower quadrant, sometimes accompanied by signs of peritoneal irritation. A tender mass may be palpable on rectal examination if inflammation is adjacent to the rectum. Mild rectal bleeding may occur but is rarely significant.
Diagnosis is supported by laboratory findings such as leukocytosis and confirmed primarily through imaging. CT scanning is the most reliable diagnostic modality, with high sensitivity and specificity, demonstrating findings such as bowel wall thickening, pericolic fat inflammation, diverticula, and abscess formation. Ultrasound may be used but is more operator-dependent. Endoscopy is generally avoided during the acute phase due to risk of perforation.
Management includes antibiotic therapy targeting anaerobic and gram-negative organisms. Common regimens include ciprofloxacin plus metronidazole, trimethoprim-sulfamethoxazole plus metronidazole, or amoxicillin-clavulanate for 7–10 days. Mild cases can often be managed outpatient, while severe cases or those unable to tolerate oral intake require hospitalization and intravenous therapy. Surgical intervention may be necessary for complications such as abscesses, perforation, or peritonitis. Percutaneous drainage may be used for larger abscesses, and elective surgery may be considered after recovery to prevent recurrence.
After resolution of the acute episode, patients are advised to adopt a high-fiber diet to reduce recurrence risk. Colonoscopy is recommended to exclude underlying malignancy. Although many patients recover fully, recurrence is common, and a subset will require surgical management.
Prognosis depends on disease severity, with mortality rates increasing in advanced stages of disease. Potential complications include perforation, abscess formation, fistula development, bowel obstruction, sepsis, and rarely pylephlebitis or hepatic abscess.
Diverticulitis is an inflammatory condition of a diverticulum, which is a pouch formed by herniation of the mucosal layer through a weak point in the muscular wall of the gastrointestinal tract. While diverticula can occur throughout the GI tract, they are most commonly found in the colon, particularly where the vasa recta penetrate the bowel wall. The presence of diverticula without inflammation is referred to as diverticulosis or diverticular disease, whereas diverticulitis specifically indicates inflammation and possible infection.
The condition is more prevalent in Western populations and increases significantly with age, affecting fewer than 5% of individuals under 40 years old but up to 65–80% of those over 70. It accounts for more than 130,000 hospital admissions annually in the United States. Both males and females are affected equally. In Western countries, diverticulitis typically involves the descending and sigmoid colon, whereas right-sided disease is more common in Asian populations.
Risk factors include a low-fiber diet, which leads to decreased stool bulk and increased intraluminal pressure, obesity, sedentary lifestyle, and immunosuppression (e.g., organ transplant recipients). The underlying mechanism involves increased pressure within the colon at weak points, leading to formation of diverticula. Subsequent pressure and irritation can result in inflammation, microperforations, or infection by polymicrobial flora, particularly anaerobes and gram-negative bacteria. Complicated diverticulitis may involve abscess formation, peritonitis, or fistula development and is classified using Hinchey’s staging system.
Clinically, diverticulitis presents with variable severity. Common symptoms include low-grade fever, abdominal pain that often starts in the epigastric region and localizes to the left lower quadrant, and changes in bowel habits such as constipation or diarrhea. In severe cases, perforation may lead to peritoneal signs like guarding and rebound tenderness. Patients with fistula formation may report pneumaturia, fecaluria, or recurrent urinary tract infections.
On physical examination, tenderness is usually localized to the left lower quadrant, sometimes accompanied by signs of peritoneal irritation. A tender mass may be palpable on rectal examination if inflammation is adjacent to the rectum. Mild rectal bleeding may occur but is rarely significant.
Diagnosis is supported by laboratory findings such as leukocytosis and confirmed primarily through imaging. CT scanning is the most reliable diagnostic modality, with high sensitivity and specificity, demonstrating findings such as bowel wall thickening, pericolic fat inflammation, diverticula, and abscess formation. Ultrasound may be used but is more operator-dependent. Endoscopy is generally avoided during the acute phase due to risk of perforation.
Management includes antibiotic therapy targeting anaerobic and gram-negative organisms. Common regimens include ciprofloxacin plus metronidazole, trimethoprim-sulfamethoxazole plus metronidazole, or amoxicillin-clavulanate for 7–10 days. Mild cases can often be managed outpatient, while severe cases or those unable to tolerate oral intake require hospitalization and intravenous therapy. Surgical intervention may be necessary for complications such as abscesses, perforation, or peritonitis. Percutaneous drainage may be used for larger abscesses, and elective surgery may be considered after recovery to prevent recurrence.
After resolution of the acute episode, patients are advised to adopt a high-fiber diet to reduce recurrence risk. Colonoscopy is recommended to exclude underlying malignancy. Although many patients recover fully, recurrence is common, and a subset will require surgical management.
Prognosis depends on disease severity, with mortality rates increasing in advanced stages of disease. Potential complications include perforation, abscess formation, fistula development, bowel obstruction, sepsis, and rarely pylephlebitis or hepatic abscess.
- Published on
Febrile seizure is a seizure occurring in children between 6 months and 5 years of age associated with fever, without evidence of intracranial infection or another primary central nervous system cause. The average age of onset is around 18–22 months. It is the most common pediatric convulsive disorder, affecting approximately 2–4% of children, and typically occurs in otherwise healthy children during a systemic illness, most often viral. Febrile seizures are classified into simple and complex types. Simple febrile seizures are generalized, brief (less than 10–15 minutes), self-limited, and occur only once within a 24-hour period. Complex febrile seizures are longer than 15 minutes, may have focal features, or recur within 24 hours. Risk factors include a family history of febrile seizures, delayed neurologic development, and male sex.
The condition is usually triggered by common childhood infections, particularly viral illnesses. Frequent causes include upper respiratory infections, otitis media, gastroenteritis, and Roseola. The seizure often occurs early in the illness, sometimes coinciding with the initial rapid rise in temperature rather than the peak fever.
Clinically, children present with fever and a seizure, most commonly a generalized tonic–clonic event. The seizure may involve an initial phase of muscle rigidity followed by rhythmic jerking movements and may be associated with apnea or urinary incontinence. Most episodes are brief and resolve spontaneously within a few minutes. Other possible manifestations include staring spells, limpness, or isolated jerking movements. After the seizure, a short postictal phase with drowsiness or confusion is common. A thorough history should include the duration and characteristics of the seizure, symptoms of infection, recent immunizations, medication exposure, trauma, developmental history, and family history of seizures. Physical examination should focus on identifying the source of fever and excluding serious conditions such as meningitis, looking for signs like nuchal rigidity, bulging fontanelle, or persistent altered mental status.
Evaluation is generally minimal for simple febrile seizures. Routine laboratory testing is not required unless there is concern for a serious bacterial infection, in which case tests such as complete blood count, urinalysis, and cultures may be performed. Lumbar puncture is not routinely indicated but should be considered in certain situations, such as in children aged 12–18 months with concerning symptoms (e.g., irritability, lethargy, poor feeding), incomplete immunization status, or signs suggestive of central nervous system infection. It is also indicated in older children if there are clear signs of meningitis or persistent altered mental status. Neuroimaging and EEG are not routinely required and are reserved for atypical presentations, such as focal seizures or underlying neurologic abnormalities.
Management is primarily supportive because most febrile seizures are self-limited. Initial priorities include maintaining airway, breathing, and circulation, and protecting the child from injury during the seizure. Oxygen and supportive care should be provided as needed. Pharmacologic treatment is rarely required, but benzodiazepines such as lorazepam, diazepam, or midazolam may be used for prolonged seizures or if the child is compromised. Rectal diazepam or intranasal midazolam can be effective in emergency settings. If seizures persist despite benzodiazepines, second-line agents such as phenytoin, fosphenytoin, or phenobarbital may be used. Antipyretics such as acetaminophen or ibuprofen are recommended to improve comfort, although they do not prevent recurrence of seizures. If a bacterial infection is identified, appropriate antibiotic therapy should be initiated.
The prognosis is generally excellent. About one-third of children will experience recurrence, especially those with early onset, a family history of seizures, or lower fever at the time of the initial episode. The risk of developing epilepsy later in life is only slightly increased compared to the general population, particularly in children with simple febrile seizures and normal neurologic development. Most children can be safely discharged if they return to baseline, have a normal neurologic examination, and the source of fever is identified and manageable. Parental reassurance and education are essential, as febrile seizures are typically benign. Aggressive fever control does not prevent recurrence, and long-term anticonvulsant prophylaxis is generally not recommended.
The condition is usually triggered by common childhood infections, particularly viral illnesses. Frequent causes include upper respiratory infections, otitis media, gastroenteritis, and Roseola. The seizure often occurs early in the illness, sometimes coinciding with the initial rapid rise in temperature rather than the peak fever.
Clinically, children present with fever and a seizure, most commonly a generalized tonic–clonic event. The seizure may involve an initial phase of muscle rigidity followed by rhythmic jerking movements and may be associated with apnea or urinary incontinence. Most episodes are brief and resolve spontaneously within a few minutes. Other possible manifestations include staring spells, limpness, or isolated jerking movements. After the seizure, a short postictal phase with drowsiness or confusion is common. A thorough history should include the duration and characteristics of the seizure, symptoms of infection, recent immunizations, medication exposure, trauma, developmental history, and family history of seizures. Physical examination should focus on identifying the source of fever and excluding serious conditions such as meningitis, looking for signs like nuchal rigidity, bulging fontanelle, or persistent altered mental status.
Evaluation is generally minimal for simple febrile seizures. Routine laboratory testing is not required unless there is concern for a serious bacterial infection, in which case tests such as complete blood count, urinalysis, and cultures may be performed. Lumbar puncture is not routinely indicated but should be considered in certain situations, such as in children aged 12–18 months with concerning symptoms (e.g., irritability, lethargy, poor feeding), incomplete immunization status, or signs suggestive of central nervous system infection. It is also indicated in older children if there are clear signs of meningitis or persistent altered mental status. Neuroimaging and EEG are not routinely required and are reserved for atypical presentations, such as focal seizures or underlying neurologic abnormalities.
Management is primarily supportive because most febrile seizures are self-limited. Initial priorities include maintaining airway, breathing, and circulation, and protecting the child from injury during the seizure. Oxygen and supportive care should be provided as needed. Pharmacologic treatment is rarely required, but benzodiazepines such as lorazepam, diazepam, or midazolam may be used for prolonged seizures or if the child is compromised. Rectal diazepam or intranasal midazolam can be effective in emergency settings. If seizures persist despite benzodiazepines, second-line agents such as phenytoin, fosphenytoin, or phenobarbital may be used. Antipyretics such as acetaminophen or ibuprofen are recommended to improve comfort, although they do not prevent recurrence of seizures. If a bacterial infection is identified, appropriate antibiotic therapy should be initiated.
The prognosis is generally excellent. About one-third of children will experience recurrence, especially those with early onset, a family history of seizures, or lower fever at the time of the initial episode. The risk of developing epilepsy later in life is only slightly increased compared to the general population, particularly in children with simple febrile seizures and normal neurologic development. Most children can be safely discharged if they return to baseline, have a normal neurologic examination, and the source of fever is identified and manageable. Parental reassurance and education are essential, as febrile seizures are typically benign. Aggressive fever control does not prevent recurrence, and long-term anticonvulsant prophylaxis is generally not recommended.
- Published on
Infectious Disease and Microbiology – Chickenpox (Varicella)
Chickenpox is a highly contagious febrile illness of childhood caused by primary infection with the varicella zoster virus (VZV). It is characterized by a generalized pruritic rash in which lesions at different stages of development—macules, papules, vesicles, pustules, and crusts—are present simultaneously.
The disease occurs worldwide and shows seasonal peaks in late winter and early spring. Before widespread vaccination, the primary attack rate in susceptible individuals was approximately 90%, with household secondary attack rates of 70–90%. Since implementation of routine vaccination programs, incidence, hospitalizations, complications, and deaths have declined dramatically. Both sexes are equally affected. Most cases occur in young children, although an increasing proportion of cases now occur in adolescents and adults in partially vaccinated populations.
Risk factors include close contact with an infected individual (varicella or herpes zoster), lack of immunity, and increasing age at exposure. Approximately 90% of individuals aged 15 years or older are immune, but 10% remain susceptible. Adults, pregnant women, and immunocompromised individuals are at higher risk for severe disease and complications.
Varicella zoster virus is a DNA virus (human herpesvirus 3) in the Herpesviridae family. Humans are the only known reservoir. Transmission occurs via respiratory droplets or direct contact with vesicular fluid. The virus enters through the respiratory mucosa, replicates in regional lymph nodes, and spreads through primary viremia. A secondary viremia disseminates the virus to the skin and other organs. After primary infection, the virus remains latent in sensory ganglia and may reactivate later in life as herpes zoster.
The incubation period is typically 10–14 days (range 10–21 days). Patients are infectious from approximately 48 hours before rash onset until all lesions have crusted. In immunocompetent children, mild prodromal symptoms such as malaise and low-grade fever may precede the rash by 1–2 days. The rash begins on the face and trunk and spreads centrifugally, sometimes involving mucous membranes. Lesions evolve rapidly from macules to papules and then to clear vesicles on an erythematous base. Vesicular fluid becomes turbid, crusting follows, and new crops of lesions appear over 2–4 days. Crusts fall off within 1–2 weeks and usually do not scar unless secondarily infected.
In immunocompromised patients, lesions are more numerous, may have hemorrhagic bases, and heal more slowly. Visceral complications occur in 30–50% of severe cases and can be fatal. Adults typically experience more severe illness and have a higher risk of complications. Pregnant women are at increased risk of varicella pneumonia and may transmit infection to the fetus. Perinatal varicella (maternal infection 5 days before to 2 days after delivery) can result in severe neonatal disease with high mortality. Congenital varicella syndrome, occurring when infection develops in the first two trimesters, may cause limb hypoplasia, skin scarring, ocular abnormalities, and central nervous system impairment.
Diagnosis is primarily clinical, based on the characteristic rash. Laboratory confirmation can be obtained by PCR detection of VZV DNA from lesion specimens, which is the most reliable method. Viral culture, direct immunofluorescence staining, Tzanck smear (showing multinucleated giant cells), and serologic testing may also be used. Chest radiographs may show nodular or interstitial infiltrates in cases of varicella pneumonia.
Differential diagnosis includes disseminated herpes simplex infection, enteroviral rashes, scabies, dermatitis herpetiformis, folliculitis, atypical measles, and rickettsialpox.
Oral acyclovir is recommended within 24 hours of rash onset to reduce disease severity. In immunocompetent children aged ≥2 years and weighing ≤40 kg, the dose is 80 mg/kg/day divided into four doses (maximum 3200 mg/day) for 5 days. Older children and adults may receive 3200 mg/day in four divided doses for 5 days. Adequate hydration is important. Valacyclovir and famciclovir are alternatives for older children and adults. Supportive care includes bathing, antipruritic agents, trimmed fingernails to prevent excoriation, and acetaminophen for fever. Aspirin should be avoided due to the risk of Reye’s syndrome.
Passive immunization with varicella zoster immunoglobulin is recommended for high-risk susceptible individuals after exposure, including immunocompromised persons, pregnant women, certain premature infants, and newborns exposed perinatally. It should be administered ideally within 72 hours and no later than 96 hours after exposure.
Active immunization with the live attenuated varicella vaccine is part of routine childhood vaccination schedules. Two doses are recommended, beginning at 12–15 months of age, with a second dose at 4–6 years. Unvaccinated adolescents and adults without evidence of immunity should receive two doses separated by at least 28 days. Vaccination is contraindicated during pregnancy.
Prognosis in healthy children is excellent, and infection usually confers lifelong immunity. However, severe disease may occur in adults, immunocompromised patients, pregnant women, and neonates. The virus remains latent and may later reactivate as herpes zoster.
Complications include secondary bacterial skin infections (commonly due to staphylococci or group A streptococci), varicella pneumonia (particularly in adults and pregnant women), cerebellar ataxia, encephalitis, meningitis, transverse myelitis, myocarditis, nephritis, hepatitis, bleeding disorders, and Reye’s syndrome. Mortality is low in the post-vaccination era but remains significant in high-risk groups.
Chickenpox is a highly contagious febrile illness of childhood caused by primary infection with the varicella zoster virus (VZV). It is characterized by a generalized pruritic rash in which lesions at different stages of development—macules, papules, vesicles, pustules, and crusts—are present simultaneously.
The disease occurs worldwide and shows seasonal peaks in late winter and early spring. Before widespread vaccination, the primary attack rate in susceptible individuals was approximately 90%, with household secondary attack rates of 70–90%. Since implementation of routine vaccination programs, incidence, hospitalizations, complications, and deaths have declined dramatically. Both sexes are equally affected. Most cases occur in young children, although an increasing proportion of cases now occur in adolescents and adults in partially vaccinated populations.
Risk factors include close contact with an infected individual (varicella or herpes zoster), lack of immunity, and increasing age at exposure. Approximately 90% of individuals aged 15 years or older are immune, but 10% remain susceptible. Adults, pregnant women, and immunocompromised individuals are at higher risk for severe disease and complications.
Varicella zoster virus is a DNA virus (human herpesvirus 3) in the Herpesviridae family. Humans are the only known reservoir. Transmission occurs via respiratory droplets or direct contact with vesicular fluid. The virus enters through the respiratory mucosa, replicates in regional lymph nodes, and spreads through primary viremia. A secondary viremia disseminates the virus to the skin and other organs. After primary infection, the virus remains latent in sensory ganglia and may reactivate later in life as herpes zoster.
The incubation period is typically 10–14 days (range 10–21 days). Patients are infectious from approximately 48 hours before rash onset until all lesions have crusted. In immunocompetent children, mild prodromal symptoms such as malaise and low-grade fever may precede the rash by 1–2 days. The rash begins on the face and trunk and spreads centrifugally, sometimes involving mucous membranes. Lesions evolve rapidly from macules to papules and then to clear vesicles on an erythematous base. Vesicular fluid becomes turbid, crusting follows, and new crops of lesions appear over 2–4 days. Crusts fall off within 1–2 weeks and usually do not scar unless secondarily infected.
In immunocompromised patients, lesions are more numerous, may have hemorrhagic bases, and heal more slowly. Visceral complications occur in 30–50% of severe cases and can be fatal. Adults typically experience more severe illness and have a higher risk of complications. Pregnant women are at increased risk of varicella pneumonia and may transmit infection to the fetus. Perinatal varicella (maternal infection 5 days before to 2 days after delivery) can result in severe neonatal disease with high mortality. Congenital varicella syndrome, occurring when infection develops in the first two trimesters, may cause limb hypoplasia, skin scarring, ocular abnormalities, and central nervous system impairment.
Diagnosis is primarily clinical, based on the characteristic rash. Laboratory confirmation can be obtained by PCR detection of VZV DNA from lesion specimens, which is the most reliable method. Viral culture, direct immunofluorescence staining, Tzanck smear (showing multinucleated giant cells), and serologic testing may also be used. Chest radiographs may show nodular or interstitial infiltrates in cases of varicella pneumonia.
Differential diagnosis includes disseminated herpes simplex infection, enteroviral rashes, scabies, dermatitis herpetiformis, folliculitis, atypical measles, and rickettsialpox.
Oral acyclovir is recommended within 24 hours of rash onset to reduce disease severity. In immunocompetent children aged ≥2 years and weighing ≤40 kg, the dose is 80 mg/kg/day divided into four doses (maximum 3200 mg/day) for 5 days. Older children and adults may receive 3200 mg/day in four divided doses for 5 days. Adequate hydration is important. Valacyclovir and famciclovir are alternatives for older children and adults. Supportive care includes bathing, antipruritic agents, trimmed fingernails to prevent excoriation, and acetaminophen for fever. Aspirin should be avoided due to the risk of Reye’s syndrome.
Passive immunization with varicella zoster immunoglobulin is recommended for high-risk susceptible individuals after exposure, including immunocompromised persons, pregnant women, certain premature infants, and newborns exposed perinatally. It should be administered ideally within 72 hours and no later than 96 hours after exposure.
Active immunization with the live attenuated varicella vaccine is part of routine childhood vaccination schedules. Two doses are recommended, beginning at 12–15 months of age, with a second dose at 4–6 years. Unvaccinated adolescents and adults without evidence of immunity should receive two doses separated by at least 28 days. Vaccination is contraindicated during pregnancy.
Prognosis in healthy children is excellent, and infection usually confers lifelong immunity. However, severe disease may occur in adults, immunocompromised patients, pregnant women, and neonates. The virus remains latent and may later reactivate as herpes zoster.
Complications include secondary bacterial skin infections (commonly due to staphylococci or group A streptococci), varicella pneumonia (particularly in adults and pregnant women), cerebellar ataxia, encephalitis, meningitis, transverse myelitis, myocarditis, nephritis, hepatitis, bleeding disorders, and Reye’s syndrome. Mortality is low in the post-vaccination era but remains significant in high-risk groups.
- Published on
Infectious Disease and Microbiology – Chancroid
Chancroid is a sexually transmitted infection characterized by painful genital lesions that may progress to ulceration. The primary lesion typically begins as a tender papule or pustule measuring 2–20 mm in diameter, which rapidly becomes an excavated ulcer with undermined, ragged, or irregular edges.
In the United States, chancroid is rare and usually occurs in localized outbreaks. Only a small number of cases are reported annually, although underdiagnosis is possible. Globally, the disease remains prevalent in parts of Africa, Asia, and Latin America, and in lower socioeconomic populations in the United States.
Risk factors include multiple sexual partners, sexual contact with an infected partner, and travel to or sexual contact with persons from endemic regions. Chancroid increases both transmission of and susceptibility to HIV infection. Approximately 10% of individuals with chancroid acquired in the United States are coinfected with Treponema pallidum (syphilis) or herpes simplex virus (HSV).
The causative agent is Haemophilus ducreyi, a small, fastidious gram-negative rod. The incubation period ranges from 1 to 14 days.
Clinically, tender papules develop at the site of inoculation and become pustular, eroded, and ulcerated within 1–2 days. Multiple lesions may coalesce to form a large ulcer exceeding 2 cm in diameter. Approximately 40% of patients develop tender inguinal lymphadenopathy (“buboes”), which may suppurate and rupture spontaneously. The combination of painful genital ulcers and suppurative inguinal lymphadenopathy is characteristic.
Diagnosis is often based on clinical and epidemiologic features, but misdiagnosis is common; laboratory confirmation is important. Definitive diagnosis requires isolation of H. ducreyi on specialized culture media, which are not widely available. Culture has approximately 80% sensitivity. Polymerase chain reaction (PCR) testing has higher sensitivity (about 95%) but is not widely available and is not FDA approved in many settings. Diagnosis also requires exclusion of syphilis (negative dark-field examination or serology performed more than 7 days after ulcer onset) and genital herpes (negative clinical and laboratory findings). All patients should be tested for HIV at diagnosis.
For specimen collection, the lesion may be gently abraded to obtain exudate, which can be applied to slides for microscopy when indicated. Histopathologic examination typically shows superficial purulent exudate and mononuclear cell infiltrates in the dermis; neutrophil infiltration may be reduced in HIV-infected patients.
The differential diagnosis includes genital herpes, syphilis, acute HIV infection, lymphogranuloma venereum, granuloma inguinale (donovanosis), mycobacterial or fungal infections, parasitic infections, venereal warts, scabies, molluscum contagiosum, folliculitis, and plague. Noninfectious causes such as malignancy, trauma, fixed drug eruptions, Behçet syndrome, and dermatitis herpetiformis should also be considered.
First-line treatment options include azithromycin 1 g orally as a single dose or ceftriaxone 250 mg intramuscularly as a single dose. Alternative regimens include ciprofloxacin 500 mg orally twice daily for 3 days or erythromycin base 500 mg orally four times daily for 7 days. Ciprofloxacin is contraindicated in pregnancy and lactation. Some isolates with intermediate resistance to ciprofloxacin or erythromycin have been reported. Sexual partners within 10 days preceding symptom onset should be evaluated and treated with the same regimen.
Fluctuant buboes may require needle aspiration through intact skin or incision and drainage; incision and drainage may reduce the need for repeated procedures.
Patients should be reexamined within 3–7 days to assess clinical improvement. Complete healing depends on ulcer size; larger ulcers may require more than two weeks to resolve. Healing may be slower in uncircumcised men with subpreputial ulcers. Failure to improve may indicate incorrect diagnosis, coinfection (e.g., syphilis), reinfection, antimicrobial resistance, noncompliance, or HIV infection. Patients with initial negative HIV or syphilis tests should be retested approximately three months later.
Complications include secondary ulcers, draining fistulas following lymph node rupture, and increased risk of HIV transmission. Education on safe-sex practices is essential to prevent recurrence and transmission.
Chancroid is a sexually transmitted infection characterized by painful genital lesions that may progress to ulceration. The primary lesion typically begins as a tender papule or pustule measuring 2–20 mm in diameter, which rapidly becomes an excavated ulcer with undermined, ragged, or irregular edges.
In the United States, chancroid is rare and usually occurs in localized outbreaks. Only a small number of cases are reported annually, although underdiagnosis is possible. Globally, the disease remains prevalent in parts of Africa, Asia, and Latin America, and in lower socioeconomic populations in the United States.
Risk factors include multiple sexual partners, sexual contact with an infected partner, and travel to or sexual contact with persons from endemic regions. Chancroid increases both transmission of and susceptibility to HIV infection. Approximately 10% of individuals with chancroid acquired in the United States are coinfected with Treponema pallidum (syphilis) or herpes simplex virus (HSV).
The causative agent is Haemophilus ducreyi, a small, fastidious gram-negative rod. The incubation period ranges from 1 to 14 days.
Clinically, tender papules develop at the site of inoculation and become pustular, eroded, and ulcerated within 1–2 days. Multiple lesions may coalesce to form a large ulcer exceeding 2 cm in diameter. Approximately 40% of patients develop tender inguinal lymphadenopathy (“buboes”), which may suppurate and rupture spontaneously. The combination of painful genital ulcers and suppurative inguinal lymphadenopathy is characteristic.
Diagnosis is often based on clinical and epidemiologic features, but misdiagnosis is common; laboratory confirmation is important. Definitive diagnosis requires isolation of H. ducreyi on specialized culture media, which are not widely available. Culture has approximately 80% sensitivity. Polymerase chain reaction (PCR) testing has higher sensitivity (about 95%) but is not widely available and is not FDA approved in many settings. Diagnosis also requires exclusion of syphilis (negative dark-field examination or serology performed more than 7 days after ulcer onset) and genital herpes (negative clinical and laboratory findings). All patients should be tested for HIV at diagnosis.
For specimen collection, the lesion may be gently abraded to obtain exudate, which can be applied to slides for microscopy when indicated. Histopathologic examination typically shows superficial purulent exudate and mononuclear cell infiltrates in the dermis; neutrophil infiltration may be reduced in HIV-infected patients.
The differential diagnosis includes genital herpes, syphilis, acute HIV infection, lymphogranuloma venereum, granuloma inguinale (donovanosis), mycobacterial or fungal infections, parasitic infections, venereal warts, scabies, molluscum contagiosum, folliculitis, and plague. Noninfectious causes such as malignancy, trauma, fixed drug eruptions, Behçet syndrome, and dermatitis herpetiformis should also be considered.
First-line treatment options include azithromycin 1 g orally as a single dose or ceftriaxone 250 mg intramuscularly as a single dose. Alternative regimens include ciprofloxacin 500 mg orally twice daily for 3 days or erythromycin base 500 mg orally four times daily for 7 days. Ciprofloxacin is contraindicated in pregnancy and lactation. Some isolates with intermediate resistance to ciprofloxacin or erythromycin have been reported. Sexual partners within 10 days preceding symptom onset should be evaluated and treated with the same regimen.
Fluctuant buboes may require needle aspiration through intact skin or incision and drainage; incision and drainage may reduce the need for repeated procedures.
Patients should be reexamined within 3–7 days to assess clinical improvement. Complete healing depends on ulcer size; larger ulcers may require more than two weeks to resolve. Healing may be slower in uncircumcised men with subpreputial ulcers. Failure to improve may indicate incorrect diagnosis, coinfection (e.g., syphilis), reinfection, antimicrobial resistance, noncompliance, or HIV infection. Patients with initial negative HIV or syphilis tests should be retested approximately three months later.
Complications include secondary ulcers, draining fistulas following lymph node rupture, and increased risk of HIV transmission. Education on safe-sex practices is essential to prevent recurrence and transmission.
- Published on
Infectious Disease and Microbiology – Cat-Scratch Disease (Bartonella Infections)
Cat-scratch disease is typically a self-limited acute illness characterized by regional lymphadenopathy with or without fever and constitutional symptoms. It is most commonly caused by Bartonella henselae. In addition to classic lymphadenitis, B. henselae infection may present as fever of unknown origin, hepatosplenic granulomatous disease, neuroretinitis, or encephalopathy. Other medically important Bartonella species include Bartonella quintana, the historical cause of trench fever and a cause of persistent bacteremia, endocarditis, and bacillary angiomatosis, and Bartonella bacilliformis, which causes Oroya fever.
In the United States, the incidence of cat-scratch disease is approximately 10 cases per 100,000 person-years, with an estimated 24,000 recognized cases annually. The disease occurs worldwide and shows seasonal variation in temperate climates, with most cases occurring between August and January. It primarily affects immunocompetent individuals, and about 80% of cases occur in persons younger than 21 years. Most cases are self-limited and present with regional adenopathy. Bartonella quintana is globally endemic and associated with body louse transmission, while Bartonella bacilliformis is transmitted by sand flies and occurs at altitudes above 1 km in the Andes.
Cats, particularly kittens and those infested with fleas, are the natural reservoir of B. henselae. A history of cat exposure is reported in approximately 90% of patients, and about 60% recall a scratch. B. quintana outbreaks are associated with homelessness and poor socioeconomic conditions, where infestation with the human body louse (Pediculus humanus) facilitates transmission. Immunocompromised patients, especially those with advanced HIV infection, are at increased risk of chronic Bartonella infections such as bacillary angiomatosis and bacillary peliosis.
Prevention includes limiting exposure to cat scratches, bites, and licks, especially in immunocompromised individuals. Control of cat fleas may reduce transmission risk.
Bartonella species are fastidious, gram-negative, aerobic rod-shaped bacteria capable of intracellular survival. Infection leads to an inflammatory response and granuloma formation, particularly in lymph nodes. B. henselae accounts for the vast majority of cat-scratch disease cases.
The illness often begins with a small erythematous papule or pustule at the site of inoculation that may persist for weeks. Regional lymph nodes draining the affected area enlarge and become tender. Fever and malaise occur in approximately 30% of patients. Neuroretinitis may present with decreased visual acuity, and encephalopathy may manifest as mental status changes. In HIV-infected individuals, B. henselae bacteremia may cause progressive fatigue, weight loss, recurrent fevers, and hepatomegaly.
Trench fever due to B. quintana typically presents after an incubation period of 3–38 days with sudden onset of chills and fever. Symptoms such as headache, retro-orbital pain, and conjunctival injection are nonspecific. Bacillary angiomatosis presents with red-to-purple papules or nodules that may ulcerate or bleed. Bacillary peliosis involves blood-filled cystic lesions within visceral organs such as the liver or spleen.
On physical examination, regional lymphadenopathy is the most common finding. A primary inoculation lesion may be visible. Parinaud’s oculoglandular syndrome, characterized by conjunctivitis, conjunctival granuloma, and preauricular lymphadenopathy, occurs in approximately 5% of patients. Visceral involvement may produce hepatosplenomegaly.
Laboratory findings may show mild leukocytosis with occasional eosinophilia. Bartonella species can be isolated from blood using specialized culture techniques. Serologic testing with indirect fluorescence assays is widely used; titers greater than 1:256 strongly suggest active infection. If results are equivocal, repeat serology after two weeks may assist diagnosis. Ultrasound of enlarged lymph nodes may help evaluate suppuration and guide aspiration. Histopathology typically shows granuloma formation, and special stains such as Warthin–Starry or tissue PCR may support the diagnosis.
Diagnosis is suggested by compatible clinical findings, history of cat exposure, positive serology, characteristic histopathology, and exclusion of other causes of lymphadenopathy, particularly mycobacterial infections and suppurative adenitis.
Although cat-scratch disease is usually self-limited, antibiotics may hasten resolution. Azithromycin (500 mg orally once, then 250 mg daily for four additional days) is commonly used in adults. Neuroretinitis has been treated with doxycycline plus rifampin, although evidence is limited. Bacillary angiomatosis limited to the skin is treated with erythromycin (500 mg four times daily) or doxycycline (100 mg twice daily) for 8–12 weeks. Bacteremia requires at least four weeks of therapy, and longer courses (2–3 months) are recommended in HIV-infected patients, persistent fever, or endocarditis. Alternative agents include rifampin, ciprofloxacin, and trimethoprim-sulfamethoxazole.
If lymph node suppuration occurs, needle aspiration is preferred over incision and drainage to relieve pain and promote recovery. Valve replacement may be required in Bartonella endocarditis.
Lymphadenopathy usually resolves over several months. One episode appears to confer lifelong immunity. In immunocompetent individuals, fever resolves promptly with or without therapy. In HIV-infected patients, resolution of fever may take longer, although bacteremia typically clears within a week of treatment.
Uncomplicated cat-scratch disease has an excellent prognosis. Complications, including retinitis, encephalopathy, or severe systemic disease, occur in 5–14% of cases. Encephalopathy typically develops weeks after the acute illness and may present with seizures; recovery is usually rapid. Inflammatory organ involvement without angiomatosis or peliosis has been reported in patients with AIDS, affecting the liver, spleen, lymph nodes, heart, and bone marrow.
Cat-scratch disease is typically a self-limited acute illness characterized by regional lymphadenopathy with or without fever and constitutional symptoms. It is most commonly caused by Bartonella henselae. In addition to classic lymphadenitis, B. henselae infection may present as fever of unknown origin, hepatosplenic granulomatous disease, neuroretinitis, or encephalopathy. Other medically important Bartonella species include Bartonella quintana, the historical cause of trench fever and a cause of persistent bacteremia, endocarditis, and bacillary angiomatosis, and Bartonella bacilliformis, which causes Oroya fever.
In the United States, the incidence of cat-scratch disease is approximately 10 cases per 100,000 person-years, with an estimated 24,000 recognized cases annually. The disease occurs worldwide and shows seasonal variation in temperate climates, with most cases occurring between August and January. It primarily affects immunocompetent individuals, and about 80% of cases occur in persons younger than 21 years. Most cases are self-limited and present with regional adenopathy. Bartonella quintana is globally endemic and associated with body louse transmission, while Bartonella bacilliformis is transmitted by sand flies and occurs at altitudes above 1 km in the Andes.
Cats, particularly kittens and those infested with fleas, are the natural reservoir of B. henselae. A history of cat exposure is reported in approximately 90% of patients, and about 60% recall a scratch. B. quintana outbreaks are associated with homelessness and poor socioeconomic conditions, where infestation with the human body louse (Pediculus humanus) facilitates transmission. Immunocompromised patients, especially those with advanced HIV infection, are at increased risk of chronic Bartonella infections such as bacillary angiomatosis and bacillary peliosis.
Prevention includes limiting exposure to cat scratches, bites, and licks, especially in immunocompromised individuals. Control of cat fleas may reduce transmission risk.
Bartonella species are fastidious, gram-negative, aerobic rod-shaped bacteria capable of intracellular survival. Infection leads to an inflammatory response and granuloma formation, particularly in lymph nodes. B. henselae accounts for the vast majority of cat-scratch disease cases.
The illness often begins with a small erythematous papule or pustule at the site of inoculation that may persist for weeks. Regional lymph nodes draining the affected area enlarge and become tender. Fever and malaise occur in approximately 30% of patients. Neuroretinitis may present with decreased visual acuity, and encephalopathy may manifest as mental status changes. In HIV-infected individuals, B. henselae bacteremia may cause progressive fatigue, weight loss, recurrent fevers, and hepatomegaly.
Trench fever due to B. quintana typically presents after an incubation period of 3–38 days with sudden onset of chills and fever. Symptoms such as headache, retro-orbital pain, and conjunctival injection are nonspecific. Bacillary angiomatosis presents with red-to-purple papules or nodules that may ulcerate or bleed. Bacillary peliosis involves blood-filled cystic lesions within visceral organs such as the liver or spleen.
On physical examination, regional lymphadenopathy is the most common finding. A primary inoculation lesion may be visible. Parinaud’s oculoglandular syndrome, characterized by conjunctivitis, conjunctival granuloma, and preauricular lymphadenopathy, occurs in approximately 5% of patients. Visceral involvement may produce hepatosplenomegaly.
Laboratory findings may show mild leukocytosis with occasional eosinophilia. Bartonella species can be isolated from blood using specialized culture techniques. Serologic testing with indirect fluorescence assays is widely used; titers greater than 1:256 strongly suggest active infection. If results are equivocal, repeat serology after two weeks may assist diagnosis. Ultrasound of enlarged lymph nodes may help evaluate suppuration and guide aspiration. Histopathology typically shows granuloma formation, and special stains such as Warthin–Starry or tissue PCR may support the diagnosis.
Diagnosis is suggested by compatible clinical findings, history of cat exposure, positive serology, characteristic histopathology, and exclusion of other causes of lymphadenopathy, particularly mycobacterial infections and suppurative adenitis.
Although cat-scratch disease is usually self-limited, antibiotics may hasten resolution. Azithromycin (500 mg orally once, then 250 mg daily for four additional days) is commonly used in adults. Neuroretinitis has been treated with doxycycline plus rifampin, although evidence is limited. Bacillary angiomatosis limited to the skin is treated with erythromycin (500 mg four times daily) or doxycycline (100 mg twice daily) for 8–12 weeks. Bacteremia requires at least four weeks of therapy, and longer courses (2–3 months) are recommended in HIV-infected patients, persistent fever, or endocarditis. Alternative agents include rifampin, ciprofloxacin, and trimethoprim-sulfamethoxazole.
If lymph node suppuration occurs, needle aspiration is preferred over incision and drainage to relieve pain and promote recovery. Valve replacement may be required in Bartonella endocarditis.
Lymphadenopathy usually resolves over several months. One episode appears to confer lifelong immunity. In immunocompetent individuals, fever resolves promptly with or without therapy. In HIV-infected patients, resolution of fever may take longer, although bacteremia typically clears within a week of treatment.
Uncomplicated cat-scratch disease has an excellent prognosis. Complications, including retinitis, encephalopathy, or severe systemic disease, occur in 5–14% of cases. Encephalopathy typically develops weeks after the acute illness and may present with seizures; recovery is usually rapid. Inflammatory organ involvement without angiomatosis or peliosis has been reported in patients with AIDS, affecting the liver, spleen, lymph nodes, heart, and bone marrow.
- Published on
Infectious Disease and Microbiology – Dengue
Dengue is a mosquito-borne viral illness that causes a severe flu-like disease and, in some cases, progresses to life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), with a fatality rate of approximately 1–5% in severe cases. It is caused by the dengue virus, a single-stranded RNA virus of the Flaviviridae family, with four antigenically distinct serotypes (types 1–4). Humans and nonhuman primates serve as reservoirs. Transmission occurs through the bite of infected Aedes aegypti and Aedes albopictus, which are predominantly day-biting mosquitoes.
Globally, about 2.5 billion people—nearly two-fifths of the world’s population—are at risk of infection. An estimated 50–100 million infections occur annually, including approximately 500,000 cases of DHF and hundreds of thousands of deaths worldwide. Transmission increases during the rainy season due to mosquito breeding in stagnant water. Dengue is endemic in around 100 countries across Asia, the Pacific, the Americas, Africa, and the Caribbean, primarily in tropical and subtropical urban and suburban areas.
The principal risk factor is travel to or residence in endemic regions. No genetic predisposition has been clearly identified. Prevention focuses on avoiding mosquito bites and vector control. Measures include using insect repellents containing at least 30% DEET, wearing long-sleeved clothing (preferably treated with permethrin), and eliminating mosquito breeding sites such as stagnant water. Indoor insecticide use and larvicidal agents may reduce mosquito populations. Bed nets are of limited value because Aedes mosquitoes bite during the daytime.
After inoculation, the incubation period ranges from 3 to 14 days, most commonly 4–7 days. The virus initially replicates in dendritic cells and then spreads to reticuloendothelial cells, hepatocytes, and endothelial cells. Immune mediators contribute to the acute febrile illness, which typically lasts 5–7 days, with full recovery within 7–10 days in uncomplicated cases. Prior infection with a different serotype increases the risk of DHF and DSS due to immune-mediated mechanisms.
DHF and DSS usually develop between days 3 and 7 of illness, often at the end of the febrile phase. Increased capillary permeability leads to plasma leakage, hemoconcentration, pleural effusions, and ascites. Thrombocytopenia, capillary fragility, and disseminated intravascular coagulation (DIC) can result in hemorrhage ranging from petechiae to life-threatening gastrointestinal bleeding. Liver involvement may cause hepatitis and coagulopathy, which can be fatal in severe cases. Mother-to-child transmission has been documented.
Clinically, patients present with fever, headache, chills, myalgias, bone pain, rash, nausea, vomiting, abdominal pain, and anorexia. Cutaneous hyperesthesia and changes in taste may occur. Hemorrhagic manifestations include bruising, epistaxis, gum bleeding, menorrhagia, and gastrointestinal bleeding. A careful travel history is essential.
On physical examination, fever is common. Rash may appear in two phases: an initial generalized blanching macular rash followed by a morbilliform maculopapular rash that typically spares the palms and soles. Conjunctival and pharyngeal injection are frequent findings. Signs of shock—tachycardia, hypotension, and delayed capillary refill—indicate severe disease. Hepatomegaly, lymphadenopathy, mucosal bleeding, and altered mental status (suggesting encephalopathy or intracranial hemorrhage) may also be present.
Laboratory evaluation often reveals leukopenia, lymphopenia, elevated hematocrit (reflecting hemoconcentration), and thrombocytopenia. Liver transaminases are commonly elevated, and albumin may be low. Electrolyte disturbances such as hyponatremia and metabolic acidosis may occur. Coagulation studies may show prolonged PT and APTT, low fibrinogen, and elevated fibrin degradation products in DIC. Serologic testing (ELISA for IgM and IgG) is commonly used for diagnosis. Imaging may demonstrate pleural or pericardial effusions and ascites. Head CT is indicated in patients with altered consciousness.
The differential diagnosis includes malaria, yellow fever, rickettsial infections, leptospirosis, typhoid fever, viral hepatitis, meningitis, bacterial sepsis, and other viral illnesses such as influenza or chikungunya.
There is no specific antiviral treatment for dengue, DHF, or DSS. Management is supportive. Aspirin and nonsteroidal anti-inflammatory drugs should be avoided due to bleeding risk. Adequate analgesia, antipyretics (such as acetaminophen), and careful fluid management are essential. In severe cases, aggressive fluid resuscitation using isotonic crystalloids or colloids is required to maintain adequate blood pressure and organ perfusion. Advanced life support protocols should be followed in patients with shock. Blood products may be necessary in cases of severe hemorrhage. Close monitoring of fluid balance, urine output, electrolytes, and coagulation status is critical.
Hospital admission is indicated for patients with hemodynamic instability, DHF, DSS, or significant bleeding. Intensive care is required for hypotension, DIC, or organ failure. Discharge is appropriate once the patient is hemodynamically stable and has recovered clinically.
Prognosis is generally excellent for uncomplicated dengue fever, with most patients recovering fully. Those who survive the critical phase of DHF or DSS usually recover without long-term sequelae. However, complications may include neurological manifestations (encephalopathy, seizures, Guillain–Barré syndrome, transverse myelitis), myocarditis, and liver failure. Cases should be reported to public health authorities, and patients should be informed that infection with a different serotype in the future increases the risk of severe disease.
